comparemela.com

Latest Breaking News On - John deanfield - Page 2 : comparemela.com

Novo's weight-loss drug could be taken for life, expert says – POLITICO

A study found that treatment with Wegovy has long-term cardiovascular benefits and sustainable weight loss for patients.

Denmark
France
Danish
Sergei-gapon
John-deanfield
Rameen-shakur
Joel-saget
Claudia-chiappa
National-institute-for-cardiovascular-outcomes-research
Anglia-ruskin-university
University-of-brighton
Novo-nordisk

Ozempic Could Be Good For Your Heart Even If You Don't Lose Weight

The medicine behind Ozempic and Wegovy, called semaglutide, could have significant benefits for heart health, reducing the risk of stroke or cardiac arrest even in those who don't lose weight.

Donna-ryan
John-deanfield
European-congress-on-obesity
Novo-nordisk
University-college-london
Pennington-biomedical-research-center
Cardiovascular-outcomes
Nature-medicine
European-congress

Anti-obesity jab cuts heart attack risk, says new study - Philippine Canadian Inquirer Nationwide Filipino Newspaper

Philippine Canadian Inquirer Anti-obesity jab cuts heart attack risk, says new study News

London
City-of
United-kingdom
John-deanfield
Young
University-of-london
Novo-nordisk
Pexels-photo

Ozempic: How semaglutide drugs can help with long-term weight loss

Researchers say GLP-1 weight loss medications such as Ozempic, Rybelsus, and Wegovy are effective for long-term weight loss as well as improving heart health

John-deanfield
European-congress-on-obesity
University-college-london
Cardiovascular-outcomes

Wegovy Helps People Lose Weight and Keep It Off, Study Shows

Recent results from a 4-year study also showed Wegovy (semaglutide) delivered heart health benefits not tied to weight loss.

California
United-states
Connecticut
Yale-university
New-haven
Italy
Donna-ryan
Sun-kim
John-deanfield
Harlan-krumholz
European-congress-on-obesity
Pennington-biomedical-research-center

vimarsana © 2020. All Rights Reserved.